Human ErbB2 / HER2 ELISA Kit
$709.00
Key features and details
- Sensitivity: 8 pg/ml
- Range: 8.19 pg/ml – 2000 pg/ml
- Sample type: Cell culture supernatant, Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
-
Detection method
Colorimetric -
Sample type
Cell culture supernatant, Serum, Plasma -
Assay type
Sandwich (quantitative) -
Sensitivity
< 8 pg/ml -
Range
8.19 pg/ml – 2000 pg/ml -
Recovery
> 81 %
Sample specific recovery Sample type Average % Range Cell culture supernatant 82.77 70% – 96% Serum 91.93 76% – 106% Plasma 81.32 69% – 97% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Abcam’s ErbB2 (Epidermal Factor Growth Factor Receptor 2) Human ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human ErbB2 in serum, plasma, and cell culture supernatants.
This assay employs an antibody specific for human ErbB2 coated on a 96-well plate. Standards and samples are pipetted into the wells and ErbB2 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-human ErbB2 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of ErbB2 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
-
Notes
Optimisation may be required with urine samples.
Related products
-
Sale!
UncategorizedNeuroscience Antibodies
Original price was: $920.00.$780.00Current price is: $780.00. Add to cartThe discovery of new potential drug targets, signaling molecules and structural proteins in the brain has dramatically increased the demand for high-quality neuroscience antibodies. The research on traditional targets and pathways will continue to focus on dopamine, beta amyloid, and serotonin. We offer a wide range of tools, including pan and phospho-specific antibodies as well as peptides and proteins geared toward different areas of neuroscience research. These antibodies, particularly those applicable to studies involving various pathways leading to neurological diseases, are among the bio-reagents keenly sought by neuroscience researchers.
All BioAnalix neuroscience antibodies are carefully purified prior to delivery. Most of our production processes involve affinity chromatography purification based on the relevant epitope, further ensuring the quality of antibodies. BioAnalix has a comprehensive collection of antibodies targeting Alzheimer’s disease and other neurological diseases including Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis.
-
UncategorizedHuman GFAP ELISA Kit
$753.00 Add to cart-
Product name
Human GFAP ELISA Kit
See all GFAP kits -
Detection method
Colorimetric - …
-
-
UncategorizedIgM Antibody
$820.00 Add to cartThe IgM class of antibodies recognizes a large variety of pathogenic antigens and is highly active in cytotoxic and cytolytic reactions due to its superior activation of the complement system. IgM antibody has applications in Antibody Drug Discovery. Just a few reasons why IgM antibody can be an attractive therapeutic are listed below.
- IgM antibody can make a good biologic against cancer owing to its strong avidity as well as complement fixation property.
- For certain targets, particularly those such as glycol-epitopes on cancer cells, an IgM antibody might be the best approach.
- An IgM antibody might also be useful as a vaccine adjuvant, acting as soluble toll-like receptors through the formation of immune complexes with antigen.
- It has been suggested to use IgMs as preventive vaccine.
- The innate ability of IgM to mediate autoimmunity can be utilized to ameliorate graft rejections during transplantation procedures.
- The inflammatory control IgM antibody provides systemic exposure to self antigens could be harnessed to treat arthritis.
Recent advancements have made IgM antibody amenable to manipulation that allows further tuning of its effector function to meet the above therapeutic needs. There are several requirements for IgM antibodies to be considered as a potential standard platform, including in vitro optimization, recombinant production, and purification. IgM antibody variable chains have been manipulated using phage display technology in vitro to optimize IgM therapeutic antibody candidates. Their recombinant yields in cell culture have been improved and methods for purification have been optimized. Based on these advances an IgM therapeutics platform can be built.
-
